30.1 C
Vientiane
Tuesday, October 7, 2025
spot_img
Home Blog Page 974

Enterprises from 39 Countries Join WCIFIT, with Thailand, Hong Kong, and Sichuan in the Spotlight

CHONGQING, China, May 23, 2025 /PRNewswire/ — A news report from iChongqing: Over 1,300 enterprises from 39 countries and regions gathered in Chongqing on May 22 for the 7th Western China International Fair for Investment and Trade (WCIFIT), highlighting rising global interest in the region’s economic potential. The event drew participants from 28 Chinese provinces and the Hong Kong Special Administrative Region, showcasing the latest in trade and innovation.

The Sirius quadruped robot was developed by a company in Chongqing Liangjiang New Area and is being exhibited at the WCIFIT. (Photo/ Liu Dan)
The Sirius quadruped robot was developed by a company in Chongqing Liangjiang New Area and is being exhibited at the WCIFIT. (Photo/ Liu Dan)

The fair also featured the debut of Lingjie, the world’s first megawatt-class supercharging heavy-duty truck, co-developed by Qingling Motors and Huawei Digital Power. With ultra-fast charging and smart connectivity, it marks a major step forward in green logistics and heavy-duty transport electrification.

Centered around the theme “New Western China, New Manufacturing, New Services,” this year’s fair highlights cultivating new quality productive forces and promoting high-quality development.

56 Chinese central state-owned enterprises, 156 local state-owned enterprises, 47 Fortune Global 500 companies, 93 multinational corporations, and 286 leading private enterprises participated.

Thailand is participating as the guest country of honor, Sichuan Province continues its role as the permanent guest province, and the Hong Kong Special Administrative Region joins as the new guest city of honor.

Dr. Lalivan Karnchanachari, Vice Minister to Ministry of Foreign Affairs of Thailand, highlighted the significance of this year marking the 50th anniversary of diplomatic ties between China and Thailand. She expressed hopes for deeper cooperation with Chongqing in high value-added manufacturing, supply chains, and SME development.

At the opening ceremony, a series of major investment deals were signed, with the total amount exceeding 200 billion yuan (about 27.6 billion USD). Districts and counties across Chongqing secured agreements worth over 100 billion yuan, with more than 75% of the investment directed toward the manufacturing and modern services sectors.

Showcasing both exhibitions and themed activities, this year’s WCIFIT exhibition spans three major sections—comprehensive image, international and regional cooperation, and modern industry—covering nine halls across 110,000 square meters. A virtual exhibition hall has also been launched to extend access online.

Themed activities include 29 events focused on key areas such as the productive service industry, foreign investment, international trade, public sector engagement, and special programs hosted by the guest of honor.

 

UniXell Biotechnology announces the first patient dosed with UX-DA001, an investigational autologous iPSC based cell therapy for the treatment of Parkinson’s disease, in its Phase 1 study

SHANGHAI, May 23, 2025 /PRNewswire/ — Shanghai UniXell Biotechnology Co., Ltd. (UniXell Biotech), a biotech company dedicated to innovative cell therapies, announced the successful first administration of its proprietary Parkinson’s disease cell drug UX-DA001 in China in March 2025. The Phase I clinical trial aims to evaluate the safety, tolerability, and preliminary efficacy of UX-DA001 in patients with Parkinson’s disease.

On March 1, 2025, Dr. Li Dianyou, Director of the Functional Neurosurgery Department at Ruijin Hospital, performed the surgical path planning and the subsequent stereotactic surgery for transplantation. The successful surgery marks the official initiation of China’s first registration-directed clinical trial for an autologous iPSC-derived cell therapy for Parkinson’s disease.

The one-month postoperative follow-up revealed significant improvements in the patient’s sleep quality and motor function, with no severe adverse events reported. The first recipient of UniXell’s autologous stem cell-derived drug, UX-DA001, shared, “after receiving the stem cell treatment, I experienced a remarkable improvement in my sleep quality. I fall asleep quickly and notice gradual progress every day. Although recovery takes time, the ‘day by day improvement’ fills me with hope for the future.”

Dr. Liu Jun, Principal Investigator of the trial and Director of the Neurology Department at Ruijin Hospital, noted “current standard treatment for Parkinson’s disease primarily relies on medications to alleviate symptoms. However, after prolonged oral drug treatment, patients often experience fluctuations in efficacy and disease progression continues. In contrast, cell therapy offers the prospect of ‘one-time treatment with long-term benefits.'”

About UX-DA001 and Phase 1 Trial

UX-DA001 is an investigational autologous iPSC-derived neural progenitor cell drug. It is derived from the patient’s own peripheral blood cells, which are firstly reprogrammed into induced pluripotent stem cells and then differentiated into dopaminergic neurons in vitro. It is then transplanted into the patient’s brain through a minimally invasive surgery. UX-DA001 leverages the patient’s own cells, significantly reducing the risk of immune rejection. Patients do not require immunosuppressive drugs, thereby avoiding potential side effects such as increased infection and tumor risks, organ toxicity, and metabolic disorders, thus achieving a safer and more effective treatment that significantly improves the quality of life for patients. The UX-DA001 has received clinical trial approvals (Investigational New Drug, IND) from both the National Medical Products Administration (NMPA) of China and the U.S. Food and Drug Administration (FDA) in December 2024 and February 2025, respectively, offering UX-DA001 a potential to have implications on patients with Parkinson’s disease in not only China but also globally.

The phase 1 study is conducted at Ruijin hospital in Shanghai, China, under the guidance of Dr. Liu Jun, MD, PhD, Principal Investigator (PI). The transplantation is performed by Dr. Li Dianyou, the director of the Functional Neurosurgery Department. This clinical study is designed to evaluate the safety and tolerability of UX-DA001 cell transplantation. It also investigates whether the transplanted cells survive, integrate and improve motor function in subjects with Parkinson’s disease.

More information about this trial is available at clinicaltrials.gov (NCT#06778265).

About UniXell Biotechnology Co., Ltd.

Shanghai UniXell Biotechnology Co., Ltd. was established in 2021, specializing in the research and development of cell therapy drugs for neurological diseases, including Parkinson’s disease and epilepsy. In addition to its autologous UX-DA001, UniXell`s IND application for UX-DA002, an allogenic cell therapy for Parkinson`s disease, has been recently accepted by NMPA.

The company is equipped with a 4000 m2 R&D center and GMP facilities. It has developed four major innovative technology platforms based on reprogramming technology, stem cell differentiation technology, SISBAR lineage tracing technology, and high-precision gene editing. These platforms facilitate the development and production of neural cell drugs with higher purity and more stable efficacy, ensuring efficient and safe clinical treatment outcomes. As of the present, UniXell has successfully obtained several rounds of funding from esteemed investors, such as Hillhouse Capital, CDH Investments, Fosun Group, Sherpa Healthcare Partners, TF Capital, and Tianshi Capital, among others. This underscores the robust market confidence in its pioneering therapeutic solutions and its potential for growth.

Contact:
UniXell Biotechnology Co., Ltd.
business@unixell.com

HK Tech 300 Expo showcases hundreds of CityUHK incubated start-up innovations and achievements

HONG KONG, May 23, 2025 /PRNewswire/ — City University of Hong Kong (CityUHK) held the HK Tech 300 Expo, a large-scale innovation and entrepreneurship exhibition, from 23 to 24 May 2025 at the University campus. The two-day event brought together about 300 start-ups incubated by CityUHK with more than 60 roadshows, demonstrating how the University’s world-class research achievements and innovative ideas translate into practical applications that foster positive social changes.  

Professor Sun Dong, JP, Secretary for Innovation, Technology and Industry of the HKSAR Government (6th from left), Mr Michael Ngai, Council Chairman of CityUHK (6th from right), Professor Freddy Boey, President of CityUHK (5th from left), Professor Michael Yang Mengsu, Senior Vice-President (Innovation and Enterprise) of CityUHK (5th from right), joins distinguished guests and partners to kick off the HK Tech 300 International Start-up Competition. (Photo credit: City University of Hong Kong)
Professor Sun Dong, JP, Secretary for Innovation, Technology and Industry of the HKSAR Government (6th from left), Mr Michael Ngai, Council Chairman of CityUHK (6th from right), Professor Freddy Boey, President of CityUHK (5th from left), Professor Michael Yang Mengsu, Senior Vice-President (Innovation and Enterprise) of CityUHK (5th from right), joins distinguished guests and partners to kick off the HK Tech 300 International Start-up Competition. (Photo credit: City University of Hong Kong)

Together with the Expo Opening Ceremony today (23 May 2025), CityUHK held the Launch Ceremony of the HK Tech 300 International Start-up Competition (HK Tech 300 International Competition), further expanding its innovation footprint onto the global stage.

Presiding over the ceremony were Professor Sun Dong, JP, Secretary for Innovation, Technology and Industry of the HKSAR Government, Mr Michael Ngai, Council Chairman of CityUHK, Mr Charles Chin Ying-on, Treasurer of CityUHK, and Professor Freddy Boey, President of CityUHK.

Also attending the ceremony were Mr Chaturont Chaiyakam, Consul-General of Thailand in the HKSAR, Mrs Le Duc Hanh, Consul-General of Vietnam in the HKSAR, and representatives from the governments and partner organisations of 12 mainland cities.

Professor Sun praised CityUHK‘s efforts in supporting young talent and nurturing start-ups. “CityUHK and HK Tech 300 play a crucial role in creating a vibrant ecosystem that fosters cross-disciplinary, cross-sector and cross-industry collaboration.  We must work together to support our young entrepreneurs, providing them with necessary resources, mentorship and opportunities to enhance their ideas into impactful solutions, further bolstering the development of Hong Kong as an international I&T hub.”

In his welcome speech, Mr Ngai said the Expo marks a significant milestone in the University’s journey to promote innovation and entrepreneurship. “CityUHK is dedicated to fostering a diverse environment for young talent, leveraging the robust support of the mainland, the University’s base in Hong Kong and global connectivity to equip our next generation to become future leaders with a global vision,” he said. 

“Innovation is the beacon of future development,” said Professor Boey in his vote of thanks. “The remarkable achievements of HK Tech 300 and the start-ups are closely linked to the extensive support from, and collaboration among, the Government, industry, the University and investors. CityUHK will continue to provide a world-class platform, empowering the growth of our young talent and deep-tech start-ups.”

Since its launch in 2021, HK Tech 300, CityUHK’s flagship innovation and entrepreneurship programme, has incubated over 900 start-ups, more than 200 of which have received up to HK$1M each in angel funding. Beyond financial support and patent resources, HK Tech 300 offers extensive assistance, including business matching and co-investment opportunities, leveraging the expertise of over 250 mentors from diverse industries, alongside partnerships with more than 100 public and private institutions.

The HK Tech 300 Expo showcases nearly 300 start-ups incubated by CityUHK, offering a range of innovative solutions in the fields of Biotech & Health, ICT & AI, Advanced tech & ESG, and Fintech. The expo also features remarkable teams recognised under the Government’s “Research, Academic and Industry Sectors One-plus Scheme (RAISe+)”, as well as business proposals from the inaugural graduates of the MSc in Venture Creation programme at the CityUHK Academy of Innovation.  

CityUHK expanded the reach of HK Tech 300 to include the national region in 2022 and the Southeast Asian region in 2023. The introduction of the HK Tech 300 International Competition will foster further cross-border collaboration to address pressing global challenges.

The HK Tech 300 International Competition will be held in partnership with 11 universities and five local partners, including business chambers and incubators from nine countries and cities: Brunei, Hungary, Indonesia, Kazakhstan, Malaysia, Thailand, Turkey, Vietnam and Hong Kong SAR, numerous of universities’ Vice-Chancellors and representatives attended the competition launch ceremony. The competition aims to attract aspiring talent and start-ups to Hong Kong and the mainland, leveraging the city’s unique advantages and resources. It also empowers our local start-ups to reach the international stage and promote the University’s technology transfer, fostering closer ties between the I&E ecosystem in Hong Kong and the rest of the world.

In addition to strategic partners, co-investors and supporting organisations from overseas and Mainland China, the event attracted legislative councillors, community leaders and school principals to witness the achievements of the start-ups. More than 60 innovation start-ups and research teams are participating in the Expo roadshows, fostering fruitful exchanges of innovation and business ideas. 

China Matters’ Feature: Bridging Cultures at China-CEEC Expo: Central and Eastern European Voices in Ningbo

NINGBO, China, May 23, 2025 /PRNewswire/ — As the 2025 China-Central and Eastern European Countries Expo opened in Ningbo on May 22, cultural and business exchanges between China and the CEE region were spotlighted. Among the many contributing to this growing partnership are Vladimir Tzanev and Fang Yu, in different professions but with a shared connection to Ningbo.

The Bulgarian pianist Vladimir Tzanev has spent the past two decades working across China. But Ningbo, in eastern China’s Zhejiang Province, is where he and his family want to call home. “My children were born here—they’re Ningbo natives now,” he says in a smile. Alongside his wife, a fellow musician from Latin America, Vladimir established a music society in the city that welcomes students from all walks of life. “Music is a language that opens any door,” he says. “And here in Ningbo, we found an audience eager to listen.”

Fang Yu, meanwhile, has a different story related to the city. After years of working in Slovakia, she returned to China in 2015 and dove into trades with CEE countries. Based in Ningbo, she helps connect Chinese companies with partners from CEE countries, especially through platforms like the China-CEEC Expo. “Trades are built on human connection,” she explains. “And Ningbo is a perfect bridge.”

This year, Slovakia is one of the guest-of-honor countries of the Expo, which holds special meaning for Fang. It was during a government delegation visit from Ningbo to Slovakia that she established a connection with the city. Since then, she’s seen firsthand how face-to-face conversations and shared experiences create trust and opportunities. “When we started, few people knew about these countries or their products,” she recalled. “Now, thanks to events like the China-CEEC Expo, more products from the region are stepping into the spotlight.”

From classical music to Slovakian wine, Vladimir and Fang are helping build more than just business ties—they’re weaving personal stories into the fabric of China-CEEC cooperation. And Ningbo, with its open arms and mind, is right at the center of it all.

YouTube Link: https://www.youtube.com/watch?v=VQo35CxFus4

 

Eason Technology Limited Receives Notification from NYSE Regarding Delayed Form 20-F Filing

HONG KONG, May 23, 2025 /PRNewswire/ — Eason Technology Limited (“Eason Technology” or the “Company”) (NYSE: DXF) today announced that it received a notice from NYSE Regulation indicating that the Company is not in compliance with the continued listing standards of NYSE American LLC (“NYSE American” or the “Exchange”). The Company failed to timely file its Form 20-F for the period ended December 31, 2024 (the “2024 Form 20-F”) by the filing due date of May 15, 2025 (the “Filing Delinquency”). The Company is now subject to the procedures and requirements set forth in Section 1007 of the NYSE American Company Guide.

NYSE Regulation notified the Company that NYSE American will closely monitor the status of the Company’s 2024 Form 20-F and any subsequent delayed filings for a six-month period from the date of the Filing Delinquency until November 15, 2025 (the “Initial Cure Period”). If the Company fails to cure the Filing Delinquency within the Initial Cure Period, the Exchange may, in its sole discretion, allow the Company’s securities to be traded for up to an additional six-month period May 15, 2026 (the “Additional Cure Period”) depending on the Company’s specific circumstances. If the Exchange determines that an Additional Cure Period is not appropriate, suspension and delisting procedures will commence in accordance with the procedures set out in Section 1010 hereof. If the Exchange determines that an Additional Cure Period of up to six months is appropriate and the Company fails to file the 2024 Form 20-F and any subsequent delayed filings by the end of that period, suspension and delisting procedures will generally commence.

As disclosed in the Form 12b-25 filed by the Company on April 30, 2025, the Company was unable, without unreasonable effort or expense, to file its 2024 Form 20-F as a result of a delay in completing its financial statements for the period ended December 31, 2024. The Company was not able to make the required filing by May 15, 2025. The Company is making all efforts to file the 2024 Form 20-F as soon as possible and within the Initial Cure Period. However, there can be no assurance that the Company will ultimately regain compliance with all applicable Exchange listing standards.

This delinquency notice has no immediate impact on the listing of the Company’s ADSs, which will continue to be listed and traded on the NYSE American during the cure period subject to continued compliance with the other listing requirements of the NYSE American.

About Eason Technology Limited

Eason Technology Limited is a company engaged in real estate operation management and investment and digital technology security business in Hong Kong, China.

Safe Harbor Statement

Certain statements made in this release are “forward looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. When used in this press release, the words “estimates,” “projected,” “expects,” “anticipates,” “forecasts,” “plans,” “intends,” “believes,” “seeks,” “may,” “will,” “should,” “future,” “propose” and variations of these words or similar expressions (or the negative versions of such words or expressions) are intended to identify forward-looking statements. These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside the Company’s control, that could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements. Important factors, among others, are the ability to manage growth; ability to identify and integrate other future acquisitions; ability to obtain additional financing in the future to fund capital expenditures; fluctuations in general economic and business conditions; costs or other factors adversely affecting our profitability; litigation involving patents, intellectual property, and other matters; potential changes in the legislative and regulatory environment; a pandemic or epidemic. The forward-looking statements contained in this release are also subject to other risks and uncertainties, including those more fully described in the Company’s filings with the Securities and Exchange Commission, which are available for review at www.sec.gov. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law. Such information speaks only as of the date of this release.

Menarini Group Presents Updated Data Underscoring the Combinability of Elacestrant (ORSERDU®) in Patients with ER+, HER2- Metastatic Breast Cancer (mBC) at the ASCO 2025 Annual Meeting

  • Preliminary efficacy analysis from the elacestrant plus everolimus and ribociclib cohorts of the ELEVATE study, along with updated safety data from additional cohorts of elacestrant plus targeted therapy combination arms, will be presented.
  • These data highlight elacestrant’s potential role as an endocrine therapy backbone in combination with various targeted agents for patients with ER+/HER2- mBC.
  • The robust elacestrant clinical development program across wide-ranging studies further solidifies its potential in monotherapy and combination settings, in mBC and in early breast cancer.

FLORENCE, Italy and NEW YORK, May 23, 2025 /PRNewswire/ — The Menarini Group (“Menarini”), a leading international pharmaceutical and diagnostics company, and Stemline Therapeutics, Inc. (“Stemline”), a wholly-owned subsidiary of the Menarini Group, focused on bringing transformational oncology treatments to cancer patients, will present updated preliminary efficacy and safety results from the Phase 1b/2 ELEVATE study in patients with estrogen receptor-positive (ER+), HER2-negative (HER2-) locally advanced or metastatic breast cancer (mBC). The ELEVATE study was designed to evaluate the safety and efficacy of oral-oral combination treatment options to overcome different resistance mechanisms observed in ER+/HER2- mBC and improve patient outcomes. Additionally, various other trial-in-progress updates will be presented, investigating elacestrant’s potential to become an endocrine therapy (ET) backbone across the spectrum of breast cancer. These data will be presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting.

The ELEVATE study is comprised of six treatment regimens evaluating elacestrant in combination with CDK4/6 inhibitors (palbociclib, abemaciclib and ribociclib) and with inhibitors of the PI3K/AKT/mTOR pathway (everolimus, alpelisib and capivasertib). ELEVATE results reported at ASCO 2025 (abstract 1070/49) include updated efficacy data which demonstrate favorable preliminary progression-free survival (PFS) from the elacestrant plus ribociclib and the elacestrant plus everolimus cohorts. A recommended phase 2 dose (RP2D) was determined to be elacestrant 345 mg plus ribociclib 400 mg. The RP2D of elacestrant 345 mg plus everolimus 7.5 mg was previously reported. 

“It is encouraging to see the positive preliminary efficacy and safety results when everolimus and ribocilib, respectively, are combined with elacestrant. These findings are consistent with the promising elacestrant plus abemaciclib cohort data from the same study that was presented last December, which also demonstrated favorable preliminary efficacy and safety in this setting,” said Hope S. Rugo, MD, Director, Women’s Cancers Program and Division Chief, Breast Medical Oncology, City of Hope Comprehensive Cancer Center.  “As the progression-free survival data and safety data continue to mature across the various cohorts of the ELEVATE study, we are encouraged by elacestrant’s potential to become an endocrine therapy backbone in combination regimens for the treatment of metastatic breast cancer.” 

Additional data reported separately (abstract 1079/58) provided updated Phase 1b/2 safety results from four cohorts of the ELEVATE study, including elacestrant plus ribociclib, everolimus, alpelisib, and capivasertib. These updated preliminary results show that the combinations are consistent with the known safety profiles of each targeted therapy plus standard of care endocrine therapy.

“These data continue to underscore the potential value of elacestrant as a combination partner in the ER+/HER2- metastatic breast cancer treatment landscape,” said Elcin Barker Ergun, CEO of the Menarini Group. “We are also exploring the potential of elacestrant in other patient populations, including our currently enrolling ELEGANT study, which is designed to assess its potential benefit in early breast cancer patients with high risk of recurrence.”

In addition, the company will be presenting other data at the ASCO Annual Meeting. See below for a complete list of Menarini Stemline abstracts.

Menarini Stemline Abstracts:

Presentation Title: Elacestrant (Ela) combinations with ribociclib (Ribo) and everolimus (Eve) in patients (pts) with ER+/HER2- locally advanced or metastatic breast cancer (mBC): Update from ELEVATE, a phase (Ph) 1b/2, open-label, umbrella study.
Abstract Number: 1070
Presentation Date & Time: Monday, June 2, 9:00 AM – 12:00 PM CT
Location: Poster Bd 49
Presenting Author: Hope S. Rugo

Presentation Title: Elacestrant combinations in patients (pts) with ER+/HER2- locally advanced or metastatic breast cancer (mBC): Safety update from ELEVATE, a phase (Ph) 1b/2, open-label, umbrella study.
Abstract Number: 1079
Presentation Date & Time: Monday, June 2, 9:00 AM – 12:00 PM CT
Location: Poster Bd 58
Presenting Author: Nancy Chan

Presentation Title: ADELA: a double-blind, placebo-controlled, randomized phase 3 trial of Elacestrant (ELA) + everolimus (EVE) versus ELA + placebo (PBO) in ER+/HER2- advanced breast cancer (aBC) patients with ESR1-mutated tumors progressing on endocrine therapy (ET) + CDK4/6i.
Abstract Number: TPS1129
Presentation Date & Time: Monday, June 2, 9:00 AM – 12:00 PM CT
Location: Poster Bd 103b
Presenting Author: Antonio Llombart-Cussac

Presentation Title: ELCIN: Elacestrant in women and men with CDK4/6 Inhibitor (CDK4/6i)-naïve estrogen receptor-positive (ER+), HER2-negative (HER2-) metastatic breast cancer (mBC): an open-label multicenter phase 2 study.
Abstract Number: TPS1127
Presentation Date & Time: Monday, June 2, 9:00 AM – 12:00 PM CT
Location: Poster Bd 102b
Presenting Author: Virginia G. Kaklamani

Presentation Title: ELEGANT: Elacestrant versus standard endocrine therapy (ET) in women and men with node-positive, estrogen Receptor-positive (ER+), HER2-negative (HER2-), early breast cancer (eBC) with high risk of recurrence in a global, multicenter, randomized, open-label phase 3 study.
Abstract Number: TPS619
Presentation Date & Time: Monday, June 2, 9:00 AM – 12:00 PM CT
Location: Poster Bd 210a
Presenting Author: Aditya Bardia

Presentation Title: EORTC-2129-BCG: Elacestrant for treating ER+/HER2- breast cancer patients with ctDNA relapse (TREAT ctDNA)
Abstract Number: TPS620
Presentation Date & Time: Monday, June 2, 9:00 AM – 12:00 PM CT
Location: Poster Bd 210b
Presenting Author: Michail Ignatiadis

About The Elacestrant Clinical Development Program

Elacestrant is also being investigated in several company-sponsored clinical trials in metastatic breast cancer disease, alone or in combination with other therapies. ELEVATE (NCT05563220) is a phase 1b/2 clinical trial evaluating the safety and efficacy of elacestrant combined with alpelisib, everolimus, capivasertib, palbociclib, ribociclib or abemaciclib. ELECTRA (NCT05386108) is an open-label phase 1b/2, multicenter study evaluating elacestrant in combination with abemaciclib in patients with ER+, HER2- breast cancer. The phase 2 portion evaluates this treatment regimen in patients with brain metastases. ELCIN (NCT05596409) is a phase 2 trial evaluating the efficacy of elacestrant in patients with ER+, HER2- advanced/metastatic breast cancer who received one or two prior hormonal therapies and no prior CDK4/6 inhibitors in the metastatic setting. ADELA (NCT06382948) is a phase 3 randomized, double-blinded trial evaluating elacestrant in combination with everolimus in patients with ER+, HER2- mBC with ESR1-mut tumors. Elacestrant is also being evaluated in additional investigator-led trials, in trials conducted in collaboration with other companies, in metastatic breast cancer as well as in early disease.

About ORSERDU (elacestrant)

U.S. Indication: ORSERDU (elacestrant), 345 mg tablets, is indicated for the treatment of postmenopausal women or adult men with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, ESR1-mutated advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy.

Full prescribing information for the U.S. can be found at www.orserdu.com.

Important Safety Information

Warning and Precautions

Dyslipidemia: Hypercholesterolemia and hypertriglyceridemia occurred in patients taking ORSERDU at an incidence of 30% and 27%, respectively. The incidence of Grade 3 and 4 hypercholesterolemia and hypertriglyceridemia were 0.9% and 2.2%, respectively.  Monitor lipid profile prior to starting and periodically while taking ORSERDU.

Embryo-Fetal Toxicity: Based on findings in animals and its mechanism of action, ORSERDU can cause fetal harm when administered to a pregnant woman.  Advise pregnant women and females of reproductive potential of the potential risk to a fetus. Advise females of reproductive potential to use effective contraception during treatment with ORSERDU and for 1 week after the last dose. Advise male patients with female partners of reproductive potential to use effective contraception during treatment with ORSERDU and for 1 week after the final dose.

Adverse Reactions

Serious adverse reactions occurred in 12% of patients who received ORSERDU. Serious adverse reactions in >1% of patients who received ORSERDU were musculoskeletal pain (1.7%) and nausea (1.3%). Fatal adverse reactions occurred in 1.7% of patients who received ORSERDU, including cardiac arrest, septic shock, diverticulitis, and unknown cause (one patient each). The most common adverse reactions (>10%), including laboratory abnormalities, of ORSERDU were musculoskeletal pain (41%), nausea (35%), increased cholesterol (30%), increased AST (29%), increased triglycerides (27%), fatigue (26%), decreased hemoglobin (26%), vomiting (19%), increased ALT (17%), decreased sodium (16%), increased creatinine (16%), decreased appetite(15%), diarrhea(13%), headache (12%), constipation (12%), abdominal pain (11%), hot flush (11%), and dyspepsia (10%).

Drug interactions

Concomitant use with CYP3A4 Inducers and/or inhibitors: Avoid concomitant use of strong or moderate CYP3A4 inhibitors with ORSERDU. Avoid concomitant use of strong or moderate CYP3A4 inducers with ORSERDU.

Use in specific populations

Lactation: Advise lactating women to not breastfeed during treatment with ORSERDU and for 1 week after the last dose.
Hepatic Impairment: Avoid use of ORSERDU in patients with severe hepatic impairment (Child-Pugh C). Reduce the dose of ORSERDU in patients with moderate hepatic impairment (Child-Pugh B).
The safety and effectiveness of ORSERDU in pediatric patients have not been established.

To report SUSPECTED ADVERSE REACTIONS, contact Stemline Therapeutics, Inc. at 1-877-332-7961 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

About The Menarini Group

The Menarini Group is a leading international pharmaceutical and diagnostics company, with a turnover of $4.7 billion and over 17,000 employees. Menarini is focused on therapeutic areas with high unmet needs with products for cardiology, oncology, pneumology, gastroenterology, infectious diseases, diabetology, inflammation, and analgesia. With 18 production sites and 9 Research and Development centers, Menarini’s products are available in 140 countries worldwide.

For further information, please visit www.menarini.com.

About Stemline Therapeutics Inc.

Stemline Therapeutics, Inc. (“Stemline”), a wholly-owned subsidiary of the Menarini Group, is a commercial-stage biopharmaceutical company focused on bringing transformational oncology treatments to patients. Stemline commercializes elacestrant, an oral endocrine therapy indicated for the treatment of postmenopausal women or adult men with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, ESR1-mutated advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy, in the U.S., Europe, and other global regions. Stemline also commercializes tagraxofusp-erzs, a novel targeted therapy directed to CD123, for patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN), an aggressive hematologic cancer, in the United States, Europe, and other global regions. In addition, Stemline commercializes selinexor, an XPO1 inhibitor for multiple myeloma, in Europe. The company is also conducting multiple label-expansion studies with elacestrant and tagraxofusp in breast and hematologic cancer indications, respectively, and has an extensive clinical pipeline of additional drug candidates in various stages of development for a host of solid and hematologic cancers.

Bybit Card Rolls Out New Lucky Draw for Guaranteed Wins Including a Tesla

DUBAI, UAE, May 23, 2025 /PRNewswire/ — Bybit, the world’s second-largest cryptocurrency exchange by trading volume, is excited to celebrate the high crypto life with the Bybit Card community in a new lucky draw that guarantees rewards for all, including the ultimate prize of a Tesla Model 3.

Starting now until June 22, 2025, eligible users may simply sign up for the event, swipe ot tap to pay with their Bybit Card to receive a lucky draw ticket, and receive a reward for each ticket. The promotion is available to all eligible Bybit Card through everyday spending, with entry thresholds as low as $10 and exclusive rewards from BTC airdrop to the crypto community’s most iconic dream car.

The event features a tiered rewards structure that will reward every participant:

  • Every $10 spent with a Bybit Card earns one ticket in the lucky draw.
  • One grand prize winner will receive 35,000 USDT, equivalent to the price of a Tesla Model 3 in most markets.
  • All participants are guaranteed to win prizes from a USDT pool valued at 40,000 USDT in BTC, USDT, and PEPE
  • New cardholders can receive 50% cashback (up to 2.5 USDT) on their first $5 spend.

New users may seize the opportunity to enjoy a host of Bybit Card privileges by applying for the card right now. Once approved, they will receive an instant virtual card ready for all their crypto payment needs, and unlock access to the lucky draw with just a few clicks.

Bybit Card Rolls Out New Lucky Draw for Guaranteed Wins Including a Tesla
Bybit Card Rolls Out New Lucky Draw for Guaranteed Wins Including a Tesla

Key Features of Bybit Card:

  • Crypto convenience: spending in crypto, and cash withdrawals from any ATM worldwide that supports Mastercard for added convenience with the physical card.
  • No annual fees, up to 10% cashback and up to 8% APR.
  • Year-round perks: 100% rebates on selected partners including Netflix and Spotify, plus airport lounge access, early-bird access to Tomorrowland Brasil 2025, and seasonal benefits
  • Multi-asset support: USDC, USDT, BTC, ETH, AVAX, and more.

The promotion is on a first-come, first served basis. Terms and conditions apply. For full benefits and on-going campaigns, users may explore: Bybit Crypto Card: Your Ultimate Crypto Debit Card.

#Bybit / #TheCryptoArk / #TheBybitCard

About Bybit

Bybit is the world’s second-largest cryptocurrency exchange by trading volume, serving a global community of over 70 million users. Founded in 2018, Bybit is redefining openness in the decentralized world by creating a simpler, open and equal ecosystem for everyone. With a strong focus on Web3, Bybit partners strategically with leading blockchain protocols to provide robust infrastructure and drive on-chain innovation. Renowned for its secure custody, diverse marketplaces, intuitive user experience, and advanced blockchain tools, Bybit bridges the gap between TradFi and DeFi, empowering builders, creators, and enthusiasts to unlock the full potential of Web3. Discover the future of decentralized finance at Bybit.com.

For more details about Bybit, please visit Bybit Press
For media inquiries, please contact: media@bybit.com
For updates, please follow: Bybit’s Communities and Social Media

Discord | Facebook | Instagram | LinkedIn | Reddit | Telegram | TikTok | X | Youtube

Let There Be Light: Vivid Sydney 2025 Kicks Off

SYDNEY, May 23, 2025 /PRNewswire/ — The Harbour City has awakened in colour and creativity tonight as Vivid Sydney 2025, Australia’s largest event, has officially begun for its 15th year. Under this year’s theme of Dream, a world class curation of Light, Ideas, Music and Food await festivalgoers over 23 nights, until Saturday, 14 June.

Vivid Sydney 2025, Sydney Opera House Lighting Of The Sails. Kiss Of Light by David McDiarmid. Credit - Destination NSW
Vivid Sydney 2025, Sydney Opera House Lighting Of The Sails. Kiss Of Light by David McDiarmid. Credit – Destination NSW

This year, the festival comprises over 200 events across five unique zones around the city’s CBD, all designed to inspire wonder, expand thinking and give each visitor the opportunity to see Sydney in a new light.

Making Vivid Sydney more accessible than ever, over 75 per cent of this year’s program is free to enjoy, including the entire Vivid Light Walk, Martin Place also makes a welcome return to the festival footprint after a seven-year absence.

This year, the world’s biggest names in entertainment, food, and pop culture will feature, including, Martha Stewart, Nigella Lawson, Nick Offerman and Megan Mullally, plus Portishead’s Beth Gibbons.

Minister for Jobs and Tourism Steve Kamper said, “Sydney is ready to shine! As we mark 15 years, this world-class event continues to showcase the very best destinations and creative talent our city has to offer.

“Vivid Sydney continues to grow in scale and impact, drawing millions of visitors and reinforcing Sydney’s position as the premier destination in the Asia Pacific.

“With over 75 per cent of the program free to attend and the entire Vivid Light Walk open to everyone, it is one of the most accessible events in the country, and this year’s program has something for everyone.

“It’s a festival that unites communities, supports local businesses and boosts our visitor and night-time economies. We can’t wait to see the city light up tonight!”

Vivid Sydney 2025 kicked off at Overseas Passenger Terminal in Circular Quay for the annual First Light ceremony, featuring performances by NAISDA dancers that honoured Yolngu culture in Arnhem Land. The ceremony culminated at 6pm as Sydney Harbour burst to life with pyrotechnics, projections and installations illuminating the city’s world-famous buildings and landmarks followed by First Light Live, a free concert honouring the power and pride of First Nations music.   

Vivid Sydney runs from Friday 23 May to Saturday 14 June. For more information visit vividsydney.com.

Photo – https://laotiantimes.com/wp-content/uploads/2025/05/vividsydney2025_soh_lightingofthesails_kissoflight_davidmcdiarmid_creditdestinationnsw_hl_036-1.jpg